ATE526013T1 - Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator - Google Patents

Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator

Info

Publication number
ATE526013T1
ATE526013T1 AT07018904T AT07018904T ATE526013T1 AT E526013 T1 ATE526013 T1 AT E526013T1 AT 07018904 T AT07018904 T AT 07018904T AT 07018904 T AT07018904 T AT 07018904T AT E526013 T1 ATE526013 T1 AT E526013T1
Authority
AT
Austria
Prior art keywords
inducing ovulation
polypeptide camp
camp
mirror modulator
host
Prior art date
Application number
AT07018904T
Other languages
English (en)
Inventor
Stephen Palmer
Mark Tepper
Sean Mckenna
Michael C Macnamee
Aliza Eshkol
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE526013T1 publication Critical patent/ATE526013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT07018904T 2001-12-14 2001-12-14 Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator ATE526013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01274987A EP1463493B1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level-modulators
PCT/EP2001/014730 WO2003051344A1 (en) 2001-12-14 2001-12-14 Methods of inducing ovulation_using a non-polypeptide camp level modulator

Publications (1)

Publication Number Publication Date
ATE526013T1 true ATE526013T1 (de) 2011-10-15

Family

ID=8164724

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01274987T ATE374606T1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level- modulators
AT07018904T ATE526013T1 (de) 2001-12-14 2001-12-14 Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01274987T ATE374606T1 (de) 2001-12-14 2001-12-14 Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level- modulators

Country Status (18)

Country Link
US (1) US7507707B2 (de)
EP (2) EP1463493B1 (de)
JP (1) JP4532115B2 (de)
KR (2) KR101056916B1 (de)
CN (1) CN1582146A (de)
AT (2) ATE374606T1 (de)
AU (1) AU2002217111B2 (de)
BR (2) BR0117198A (de)
CA (1) CA2469939C (de)
DE (1) DE60130813T2 (de)
DK (2) DK1908463T3 (de)
EA (1) EA011213B1 (de)
ES (1) ES2293965T3 (de)
IL (3) IL162506A0 (de)
MX (1) MXPA04005782A (de)
PT (2) PT1463493E (de)
UA (1) UA80418C2 (de)
WO (1) WO2003051344A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05010373A (es) * 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
JP2007517828A (ja) * 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道の疾患を治療するための置換プテリジンの使用
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (de) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Kristalline form eines dihydropteridionderivats
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN103169699B (zh) * 2011-12-22 2014-11-12 中国农业大学 来曲唑在用于制备成年牛超数排卵药物中的应用
WO2014089913A1 (zh) * 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
AP2001002304A0 (en) 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
EP0952832B1 (de) 1996-05-20 2008-08-27 Darwin Discovery Limited Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
CN1219171A (zh) 1996-05-20 1999-06-09 达尔文发现有限公司 苯并呋喃甲酰胺及其治疗用途
EP0912519A1 (de) 1996-05-20 1999-05-06 Darwin Discovery Limited Chinolinsulfonamide als tnf-inhibitoren und als pde-iv-inhibitoren
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CN1080260C (zh) 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US6051718A (en) 1996-10-02 2000-04-18 Janssen Pharmaceutica, N.V. PDE IV inhibiting 2-cyanoiminoimidazole derivatives
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
DE69723863T2 (de) 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough Chinoline und deren therapeutische verwendung
JP3237109B2 (ja) * 1996-12-13 2001-12-10 田辺製薬株式会社 医薬組成物
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
HU228736B1 (en) 1998-04-23 2013-05-28 Zentaris Ivf Gmbh Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
CA2333320A1 (en) * 1998-05-26 1999-12-02 Schering Aktiengesellschaft Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
US6303789B1 (en) * 1998-06-10 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
US6316472B1 (en) * 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
EP1212089B1 (de) * 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistische kombination von roflumilast und salmeterol
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
AU2001250286A1 (en) * 2000-04-17 2001-10-30 Bioimage A/S Live cell procedures to identify compounds modulating intracellular distributionof phosphodiesterase (pde) enzymes
AU6469401A (en) * 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
ES2267778T3 (es) * 2000-06-06 2007-03-16 Glaxo Group Limited Composicion para el tratamiento del cancer, que contiene un agente anti-neoplastico y un inhibidor de pde4.
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US20020065324A1 (en) * 2000-08-11 2002-05-30 Stephen Palmer Methods of inducing ovulation
MXPA05010373A (es) * 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.

Also Published As

Publication number Publication date
CA2469939A1 (en) 2003-06-26
ES2293965T3 (es) 2008-04-01
PT1908463E (pt) 2011-12-19
PT1463493E (pt) 2008-01-04
DE60130813D1 (de) 2007-11-15
IL205106A (en) 2013-02-28
KR20090009336A (ko) 2009-01-22
WO2003051344A1 (en) 2003-06-26
ATE374606T1 (de) 2007-10-15
BR0117198A (pt) 2004-10-26
AU2002217111A1 (en) 2003-06-30
IL162506A (en) 2012-03-29
EP1908463A3 (de) 2009-11-25
EP1463493A1 (de) 2004-10-06
US20050148501A1 (en) 2005-07-07
JP4532115B2 (ja) 2010-08-25
DE60130813T2 (de) 2008-07-03
DK1463493T3 (da) 2008-02-04
KR101056916B1 (ko) 2011-08-12
BRPI0117198B1 (pt) 2018-03-13
EP1908463A2 (de) 2008-04-09
US7507707B2 (en) 2009-03-24
CA2469939C (en) 2012-06-19
IL162506A0 (en) 2005-11-20
IL205106A0 (en) 2010-11-30
KR20040075004A (ko) 2004-08-26
JP2005516924A (ja) 2005-06-09
EA200400808A1 (ru) 2004-12-30
EP1463493B1 (de) 2007-10-03
EA011213B1 (ru) 2009-02-27
AU2002217111B2 (en) 2007-05-31
EP1908463B1 (de) 2011-09-28
DK1908463T3 (da) 2011-11-28
AU2002217111B8 (en) 2003-06-30
MXPA04005782A (es) 2004-09-13
CN1582146A (zh) 2005-02-16
UA80418C2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
ATE526013T1 (de) Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator
HUP0004211A2 (hu) PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására
ATE475883T1 (de) Verfahren zur messung der wirkstärke von glatirameracetat
WO2002102314A3 (en) Purine inhibitors of phosphodiesterase (pde) 7
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
DE60110937D1 (de) Nicht isothermisches verfahren zum herstellen von hohlen verbundteilen
WO2002044156A3 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
DE60143249D1 (de) Verbinder für kartenförmige Vorrichtung
WO2001062979A3 (en) Dentification of partial agonists of the a2a adenosine receptor
ATE483691T1 (de) Verfahren zur herstellung von unsymmetrischen 4,6-bis(aryloxy)pyrimidin-derivaten
ZA200205694B (en) Treatment of diabetic ulcers.
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DE60137862D1 (de) Verfahren zur rückgewinnung von hexamethylendiamin (hmd) mit geringem polarographischen reduzierbaren verunreinigungen (prv) aus gemischen enthaltend hmd, aminocapronitril und prv
DE60233936D1 (de) Therapeutische Zusammenseztungen zur Toleranzinduktion
WO2005116195A3 (de) Methode zur identifizierung von pde5-modulatoren
DE50112690D1 (de) Verfahren zur aufbereitung von pyrrolidon- und n-vinylpyrrolidon-rückständen
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
PT1335730E (pt) Tratamento da ejaculacao prematura
WO2002003993A3 (en) Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
SE0202608D0 (sv) New sequences
SE0101242D0 (sv) Penna
WO2004098374A3 (en) System and method for enhanced medicament-based treatment of disease
MY127989A (en) Treatment of neuropathy
ITRM20010720A1 (it) Apparato e metodo per la realizzazione di fascicoli stampati.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1908463

Country of ref document: EP